Libra Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Libra Therapeutics's estimated annual revenue is currently $697.5k per year.
- Libra Therapeutics's estimated revenue per employee is $77,500
- Libra Therapeutics's total funding is $29M.
Employee Data
- Libra Therapeutics has 9 Employees.
- Libra Therapeutics grew their employee count by 0% last year.
Libra Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
Libra Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Libra Therapeutics?
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases. These include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's, Parkinson's, and Huntington's disease, which are all characterized by cellular disequilibrium caused by the production and decreased clearance of neurotoxic proteins. The company's therapeutic platform is uniquely positioned to discover and develop small molecule drugs with distinct molecular approaches that can 1) increase autophagy to more rapidly clear toxic proteins and 2) attenuate the production of neurotoxic proteins.
keywords:N/A
$29M
Total Funding
9
Number of Employees
$697.5k
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Libra Therapeutics News
Key Frontotemporal Dementia pipeline therapies in various stages of development ... In October 2021, Libra Therapeutics, Inc. announced the...
Libra Therapeutics, a biotechnology company focused on developing novel disease-modifying therapeutics, has officially launched with $29 million in Series A financing to restore the cellular balance lost in neurodegenerative diseases... Take 1 minute to subscribe and you'll get this story immed ...
Libra Therapeutics, Inc., a San Diego, CA-based developer of novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases, secured $29m in Series A financing. The round was co-led by Boehringer Ingelheim Venture Fund (BIVF), Epidarex Capital, and Santé, joi ...
San Diego-based Libra Therapeutics, a new startup developing treatments for various neurodegenerative diseases, has raised $29M in its Series A funding round, the company said this morning. According to Libra Therapeutics, the funding was co-led by Boehringer Ingelheim Venture Fund (BIVF), Epida ...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | N/A | N/A |
#2 | $0.7M | 9 | N/A | N/A |
#3 | $0.7M | 9 | N/A | N/A |
#4 | $0.7M | 9 | N/A | N/A |
#5 | $0.7M | 9 | N/A | N/A |